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Intra-tumour heterogeneity manifests at the level of mutational burden, but also at a 
functional level within genetically homogenous populations. An innovative modelling 
approach suggests that stemness within colorectal tumours is defined by 
microenvironmental cues secreted from cancer associated fibroblasts rather than cell 
intrinsic properties. 
It is well accepted that tumours display extensive cellular and molecular heterogeneity, 
making it cumbersome to identify cancer stem cells (CSCs) that sustain tumour growth1,2. 
Adult stem cells and CSCs often share molecular and growth features, which has permitted 
better characterisation of CSCs in multiple malignancies3. Previous studies have adopted an 
Lgr5+ stem cell-centric model to describe the growth dynamics of colorectal cancer (CRC)4,5, 
and have demonstrated that intestinal adenomas retain cellular hierarchy6,7. Furthermore, 
several studies have postulated the potential utility in targeting the Lgr5+ CSCs in colorectal 
cancer (CRC) patients8,9. In this issue of Nature Cell Biology, Lenos et al take an unbiased 
approach to model growth of colorectal tumours and determine that markers of stem cells, 
such as Lgr5, and stemness are not one and the same10. The authors further define that the 
tumour microenvironment is able to dictate stemness in CRC models and that tumours grow 
from the edge rather than via ubiquitous expansion of the tumour bulk. 
Through the combination of mouse models and organoid xenografts, targeted ablation of 
Lgr5+ cells in CRC has been shown to be sufficient to perturb tumour growth4,5. However, 
following cessation of Lgr5+ cell depletion, tumour expansion is immediately reinstated, 
which reveals Lgr5+ cells as a major contributor to tumour growth and demonstrates the 
impressive plasticity within CRC. The latter phenomenon indicates that in addition to cell 
intrinsic mutational burden, cell extrinsic cues dictate tumour cell fate and stemness. The 
findings in the current study indicate that cells positive for “stem cell markers” take a back 
seat, and instead the environmental cues provided by surrounding stromal cells confer 
stemness and drive tumour cell plasticity. 
Lenos et al use a marker-free tamoxifen inducible labelling system to stochastically label 
tumour cells in mouse xenograft models, employing both a traditional two-dimensional cell 
line and two patient derived spheroid lines. The sizes of individual labelled clones were 
evaluated at various time points post induction, and the distributions of clone sizes over time 
were integrated into a stochastic model of tumour growth. This model was designed to infer 
whether tumour growth is inherently driven by cells at the extreme of an intrinsic hierarchical 
structure consistent with a CSC-centric model, or dictated by extrinsic factors consistent with 
a microenvironmental niche model. 
These data indicated that all tumour lines when implanted subcutaneously into mice did not 
contain evidence of an intrinsic hierarchical organisation, and thus clonal out-growth was 
defined by environmental factors rather than cell intrinsic factors. The authors continued by 
approximating a cellular division rate of between 0.15 and 0.35 effective divisions per day for 
clonogenic cells and defining that the vast majority (>98%) of all clonogenic cells were 
housed toward the edges of the tumour. This fundamental growth dynamic of CRC was 
mimicked by orthotopic implantation of xenografts into the caecum, indicating the 
subcutaneous microenvironment is not driving a unique growth dynamic of CRC xenografts. 
In these models, the majority of proliferative cells (marked by Ki67) were located in the 
outermost 300µm of the tumour; a feature that the authors demonstrated was consistent with 
that of primary human CRC. This characteristic tumour proliferation at a holistic level is 
consistent with a model of surface tumour growth, and accurately predicted the rate of 
macroscopic tumour expansion. The authors conclude that CRC grows from surface 
expansion while the central bulk of the tumour contributes little to tumour growth (Figure 1), 
which is supported by another recent publication11. 
It has previously been reported that environmental cues are able to dictate CRC cell fate in 
xenograft models12. The authors employed an innovative enzymatic digestion technique to 
separate the outermost areas of the tumour bulk from the core region. RNA sequencing 
comparing the two populations revealed, as expected, enrichment for genes associated with 
proliferation at the tumour edge. Notably, no enrichment for stem cell signatures or 
difference in the proportion of Lgr5+ cells was detected in either population, and this was 
confirmed by RNAish and immunohistochemistry for stem cell markers. These data highlight 
the discrepancy between CSC marker expression and functionality. 
The importance of the microenvironment was again highlighted by complete plasticity within 
the tumour bulk. The authors transplanted the tumour centre following enzymatic digestion 
back into mice and observed a rapid reinstatement of surface growth features. Furthermore, 
the centre tumour cells were functionally indistinguishable from the edge cells when 
compared using an in vitro clonogenicity assay. Thus, when the environmental cues are 
identical, tumour cell plasticity enables a proliferative state regardless of their origin. It 
appears that conclusions cannot be drawn between clonogenicity assays and contribution 
towards tumour growth rates. The authors demonstrated that time to tumour establishment 
(tumour volume >100mm3) correlates with the measured clonogenicity of a cell population, 
where expansion following tumour establishment does not. 
A correlation between Ki67+ tumour cells and the distance to the nearest cancer-associated 
fibroblast (CAF) was observed, which prompted the authors to investigate the functional 
significance of CAFs and tumour epithelial growth dynamics. To test this, co-cultures were 
established, which revealed increased epithelial cell growth when cultured with CAFs. These 
findings were corroborated using conditioned medium from CAFs, indicating the importance 
of CAF secreted factors in regulating epithelial cell growth. To identify factors which may 
influence tumour growth distribution, the authors interrogated their RNA sequencing and 
identified Osteopontin (OPN) as the most highly expressed secreted factor in CAFs. Levels 
of OPN have previously been shown to be increased in solid malignancies including 
CRC13,14. Clonal analysis of OPN-overexpressing tumour cells after subcutaneous 
implantation, revealed that ubiquitous expression of OPN afforded increased proliferation to 
clones in the central tumour region and a decreased variation in clone sizes. Functionally, 
OPN overexpression also resulted in increased Ki67 positivity in the central tumour regions 
which was not associated with a change in CAF distribution throughout the tumour (Figure 
2). 
Using the stochastic clone system, the authors determined that chemotherapy with a 
combination of oxaliplatin and 5-fluorouracil suppressed rate of tumour growth, but did not 
impact fundamental tumour growth dynamics. Treated tumours contained a higher 
proportion of cells containing “stem cell markers”, such as Lgr5, but nevertheless retained a 
surface growth dynamic. These analyses provide evidence that even though “stem cell 
markers” are increased during chemotherapeutic intervention, the mode of surface tumour 
growth is unperturbed. This surface growth characteristic is dictated by microenvironmental 
influences that are not targeted by current chemotherapeutics. 
The authors provide compelling evidence that challenges the promise of directly targeting 
CSCs in primary CRC. This observation is partially supported by previous work 
demonstrating that Lgr5+ cells have an enhanced ability to establish tumours in the liver and 
subcutaneous environments but are not required for primary tumour survival5. Combining 
these data with those of the current study advocates that the ability of a cell to establish a 
tumour and to drive tumour growth should be considered as independent cellular traits. 
Furthermore, an important follow-up study will be to determine whether, in a different tumour 
microenvironment, CAFs also influence metastatic seeding and tumour growth dynamics. 
Lenos et al have elegantly described the growth kinetics and dynamics of colorectal 
tumours, and identified OPN as a secreted factor by which CAFs can dictate tumour cell 
fate. These data illuminate a previously underappreciated concept that stromal cues can 
influence tumour cell hierarchy and subsequently have profound effects upon the tumour 
mass as a whole. Importantly, this newly emphasised critical role for molecular determinants 
of stemness in established tumours shifts the focus from targeting tumour cell populations 
that express canonical stem cell markers more towards targeting the niche that provides 
tumours with their much-needed CSC lifeline. 
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Figure legend 
Figure 1. Cancer stem cells drive CRC expansion from the tumour edge. 
(A) Schematic of CRC growth dynamics over time showing tumour expansion is driven from 
the tumour edge (black arrows) and not from the centre (blue circle). 
(B) Schematic illustrating the relationship between cancer-associated fibroblasts (CAFs) and 
clonogenic cells (strawberry). Tumour cells located at the tumour edge are optimally placed 
to drive clonogenicity and tumour expansion, which is aided by secreted factors, such as 
osteopontin (OPN), from CAFs. Clonogenic cells in the tumour centre do not give rise to 
large clonal patches like the clonal cells situated at the tumour edge. The ability of a cell to 
give rise to progeny is promoted by its proximity to CAFs which are found mostly at the 
edges of the tumour. Inset shows CAF secreted OPN enhancing proliferation of Ki67+ of 
cancer cells. 
  
 
 
